Generated by AI
Intellia Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genome-editing medicines built on CRISPR/Cas9 technology. Intellia Therapeutics develops both in vivo therapies, which edit genes inside the body, and ex vivo cell therapies, where cells are edited outside the body before being returned to the patient. Its current programs are centered on severe genetic and immune-related diseases, including rare disorders such as transthyretin amyloidosis and hereditary angioedema, as well as selected oncology and autoimmune applications. The company’s broader role in the market is to advance potentially curative treatment approaches that address the root cause of disease rather than symptoms. Intellia Therapeutics operates as a research-driven biopharmaceutical company, with a business model centered on clinical development, collaboration, and platform-based innovation in genetic medicine.
Website400 Technology Square
Cambridge, MA, 02139
United States
The latest articles about NTLA.
Summary of Nov 18's posts. Generated by AI.
Summary of Sep 8's posts. Generated by AI.
Summary of Jul 1's posts. Generated by AI.
Summary of Aug 26's posts. Generated by AI.
Investors talking about NTLA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.